Institute of Child Neurology and Neurodevelopment

Biography:Eric Mallack, MD, MBE is an Assistant Professor of Pediatrics and Neurology at Weill Cornell Medical College, Assistant Attending at NewYork-Presbyterian Hospital, and Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center. He is the Director of theLeukodystrophy Centerat Weill Cornell Medicine, and Neurologist in the WCM-MSKCC Metabolic Cell and Gene Therapy Program.Dr. Mallack completed his A.B. in Philosophy and Biomathematics at The University of Scranton. He then simultaneously earned his Medical Doctorate from the Temple University School of Medicine, and his Masters Degree in Bioethics (MBE) from the University of Pennsylvania School of Medicine. Dr. Mallack completed his Pediatrics and Child Neurology Residency training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He completed his post-doctoral research training under the NIH/NINDS Neurological Sciences Academic Development Award (NSADA K12) at the Massachusetts General Hospital Center for Rare Neurological Diseases.Dr. Mallacks clinical interests include the class of diseases known as the leukodystrophies with a special interest in X-Linked Adrenoleukodystrophy, and childhood neurogenetic disorders. His research interests include gene therapy for the leukodystrophies and advanced neuroimaging.About Dr. Mallack's Research Program:Dr. Mallack's translational research program allies with the Newborn Screening Program and Patient/Parent Advocacy Groups to identify presymptomatic patients with X-Linked Adrenoleukodystrophy. He is investigating the ability of multiple advanced neuroimaging techniques, including diffusion tensor imaging, to identify patients appropriate for stem cell transplant or gene therapy prior to symptom onset.Dr. Mallack is an investigator on multiple gene therapy clinical trials:Krabbe Disease: Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease (GALax-C)Canavan Disease: A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire)Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A): Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)Dr. Mallack is a faculty neurologist in the Center for Neurogenetics which focuses on understanding the genetic mechanisms responsible for abnormal brain development. He is also investigating genotype-phenotype correlations in autism under the Weill Cornell Autism Research Project (WCARP).